A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS

OBJECTIVE: Capecitabine is an oral 5-fluorouracil (5-FU) pro-drug commonly used to treat colorectal carcinoma and other tumours. About 35% of patients experience dose-limiting toxicity. The few proven genetic biomarkers of 5-FU toxicity are rare variants and polymorphisms, respectively, at candidate...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Gut
Autori principali: Rosmarin, Dan, Palles, Claire, Pagnamenta, Alistair, Kaur, Kulvinder, Pita, Guillermo, Martin, Miguel, Domingo, Enric, Jones, Angela, Howarth, Kimberley, Freeman-Mills, Luke, Johnstone, Elaine, Wang, Haitao, Love, Sharon, Scudder, Claire, Julier, Patrick, Fernández-Rozadilla, Ceres, Ruiz-Ponte, Clara, Carracedo, Angel, Castellvi-Bel, Sergi, Castells, Antoni, Gonzalez-Neira, Anna, Taylor, Jenny, Kerr, Rachel, Kerr, David, Tomlinson, Ian
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2015
Soggetti:
Colon
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4283622/
https://ncbi.nlm.nih.gov/pubmed/24647007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2013-306571
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi